ClinicalTrials.gg

Program

nitrosomonas eutropha D23

Also written as “B244”, “Experimental: B244” and “B244 suspension”.

Its studies are mostly in Acne Vulgaris · Dermatitis, Atopic · Eczema · Rhinitis, Allergic · Migraine Disorders, led by AOBiome.

Furthest: phase 3, since Jul 8, 201610 company-led studies, 1 open or runningNext primary completion: Aug 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AOBiome101 open or runningphase 3since Jul 8, 2016Jan 11, 2016Aug 2027phase 2 · NCT07866105

Also a collaborator on its studies: biorasi-llc and integrium.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 11, 2016First study: phase 2 study in Acne VulgarisFirst studyNCT02656485 · 36 enrolled · United States
  2. Jul 8, 2016Phase 3 study in Acne VulgarisNCT02832063 · 372 enrolled · United States
  3. Nov 22, 2016Phase 2 study in PrehypertensionNCT02998840 · 132 enrolled · United States
  4. Jul 20, 2017Phase 2 study in Atopic Dermatitis EczemaNCT03235024 · 122 enrolled · United States
  5. Sep 15, 2017Phase 2 study in Rhinitis, AllergicNCT03290248 · 71 enrolled · United States, Canada
  6. Mar 26, 2018Phase 2 study in Migraine DisordersNCT03488563 · 313 enrolled · United States
  7. Jun 25, 2018Phase 2 study in RosaceaNCT03590366 · 140 enrolled · United States
  8. Dec 7, 2018Phase 1 study in EczemaNCT03775434 · 28 enrolled · United States
  9. Jul 16, 2020Phase 2 study in Dermatitis, AtopicNCT04490109 · 547 enrolled · United States
  10. Oct 5, 2026Phase 2 study in Acne VulgarisNCT07866105 · 176 planned

Ahead

  1. Aug 2027Primary completion: phase 2 study in Acne VulgarisNCT07866105

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 10 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07866105Acne Vulgaris2Not yet recruitingAug 2027176
NCT04490109Dermatitis, Atopic · United States2CompletedDec 10, 2021547
NCT03775434Eczema · United States1CompletedMay 18, 201928
NCT03590366Rosacea · United States2CompletedFeb 11, 2019140
NCT03488563Migraine Disorders · United States2CompletedJun 17, 2019313
NCT03290248Rhinitis, Allergic · United States, Canada2CompletedDec 21, 201871
NCT03235024Atopic Dermatitis Eczema · United States2CompletedFeb 27, 2019122
NCT02998840Prehypertension · United States2CompletedApr 25, 2017132
NCT02832063Acne Vulgaris · United States3CompletedJul 19, 2017372
NCT02656485Acne Vulgaris · United States2CompletedMar 1, 201636

How it is read

Names in the registry

  • “B244”, 8 entries
  • “Experimental: B244”, 1 entry
  • “B244 suspension”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.